BRIDGEWATER, N.J., Nov 29, 2007 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's chairman and chief executive officer, will present at the BMO Capital Markets Focus on Healthcare Conference, which is being held December 4-5 in New York City. Enzon's presentation will take place at 11:00 a.m. EST on Tuesday, December 4, 2007. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon's website at www.enzon.com.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777 EVP, Finance and Chief Financial Officer

Copyright Business Wire 2007

News Provided by COMTEX